BridgeBio Pharma, Inc. balance sheet BBIO

Annual Quarterly

As of Sep 30, 2026, BridgeBio Pharma, Inc. had total assets of $2.2 billion and total liabilities of $3.8 billion. Total assets were up 116.6% from a year earlier. Stockholders' equity was negative, at -$1.7 billion, because liabilities exceed assets. It held $1.5 billion in cash and investments against $2.6 billion of total debt, net debt of $1.1 billion. The current ratio, current assets divided by current liabilities, was 2.09.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019
Assets
Cash	1,533 +138.5%	570 -16.3%	681 +81.2%	376 -0.2%	377 -4.3%	394 +10.6%	356 -2.1%	364
Short-term investments	5 +83.6%	17	—	0 -100.0%	52 -86.9%	394 +56.9%	251 +37.8%	182
Long-term investments	—	—	—	—	—	—	—	31
Cash and investments	1,539 +138.2%	587 -13.7%	681 +81.2%	376 -12.2%	428 -45.6%	788 +23.4%	607 +11.2%	577
Receivables	375 +221.9%	139 +2853.1%	5	—	—	—	—	—
Inventory	60 +143.5%	27	—	—	—	—	—	—
Total current assets	2,045 +143.6%	798 +10.7%	721 +50.9%	478 -13.0%	549 -38.3%	889 +38.3%	643 +13.0%	569
Property and equipment, net	5 -13.5%	5 -23.5%	7 -40.7%	12 -18.9%	15 -51.5%	30 +47.9%	20 +261.3%	6
Total assets	2,162 +116.6%	936 +1.8%	919 +68.3%	546 -12.3%	623 -38.5%	1,013 +43.9%	704 +11.4%	632
Liabilities and equity
Accounts payable	88 +371.9%	36 +276.7%	10 -9.7%	11 -7.8%	12 -2.7%	12 +32.9%	9 +1.1%	9
Total current liabilities	977 +351.2%	288 +86.5%	154 +7.3%	144 +18.5%	121 -10.1%	135 +41.2%	96 +58.4%	60
Total liabilities	3,815 +30.6%	3,013 +26.7%	2,377 +25.8%	1,889 +1.1%	1,868 -0.6%	1,878 +215.3%	596 +282.6%	156
Stockholders' equity	-1,662 +14.0%	-2,087 -42.1%	-1,468 -8.4%	-1,354 -7.9%	-1,255 -44.1%	-870 -1603.1%	58 -85.8%	408
Debt
Debt due within a year	—	—	437 -2.0%	446 +3.6%	431 +27.4%	431 +366.1%	—	—
Long-term debt	2,630 +31.0%	2,007	—	—	—	—	94 -1.6%	95
Lease liabilities	17 +90.7%	10 +8.7%	9 -29.8%	13 -17.8%	16 -33.3%	24 +18.5%	20 +152.2%	8
Total debt	2,647 +31.3%	2,017 +351.8%	447 -2.8%	460 +2.8%	447 -2.0%	455 +303.8%	114 +10.3%	103
Net cash	-1,108 +19.1%	-1,430 -709.6%	235 +380.5%	-84 -347.8%	-19 -105.6%	333 -36.7%	493 +11.4%	474
Ratios
Current ratio	2.09x	2.77x	4.67x	3.32x	4.52x	6.58x	6.72x	9.42x
Debt to equity	—	—	—	—	—	—	1.97x	0.25x
Book value per share	-8.48	-10.71	-7.72	-7.73	-8.33	-5.91	0.47	3.30

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: BBIO (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Palo Alto, CA
SEC filer status: Large accelerated filer
SEC CIK: 1743881
Former names: BridgeBio Pharma LLC (until May 16, 2019)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.